Gerald W. Zamponi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2703476/publications.pdf

Version: 2024-02-01

328 papers 18,741 citations

75 h-index 120 g-index

498 all docs 498 docs citations

498 times ranked 14787 citing authors

#	Article	IF	Citations
1	The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. Pharmacological Reviews, 2015, 67, 821-870.	16.0	793
2	Neuronal Voltage-Gated Calcium Channels: Structure, Function, and Dysfunction. Neuron, 2014, 82, 24-45.	8.1	489
3	Crosstalk between G proteins and protein kinase C mediated by the calcium channel $\hat{l}\pm 1$ subunit. Nature, 1997, 385, 442-446.	27.8	455
4	Will the real multiple sclerosis please stand up?. Nature Reviews Neuroscience, 2012, 13, 507-514.	10.2	406
5	Splicing of $\hat{l}\pm 1A$ subunit gene generates phenotypic variants of P- and Q-type calcium channels. Nature Neuroscience, 1999, 2, 407-415.	14.8	393
6	Regulating excitability of peripheral afferents: emerging ion channel targets. Nature Neuroscience, 2014, 17, 153-163.	14.8	361
7	Protease-activated receptor 2 sensitizes the transient receptor potential vanilloid 4 ion channel to cause mechanical hyperalgesia in mice. Journal of Physiology, 2007, 578, 715-733.	2.9	338
8	Targeting voltage-gated calcium channels in neurological and psychiatric diseases. Nature Reviews Drug Discovery, 2016, 15, 19-34.	46.4	306
9	Calcium-Permeable Ion Channels in Pain Signaling. Physiological Reviews, 2014, 94, 81-140.	28.8	249
10	Direct G Protein Modulation of Cav2 Calcium Channels. Pharmacological Reviews, 2006, 58, 837-862.	16.0	226
11	Prion protein attenuates excitotoxicity by inhibiting NMDA receptors. Journal of Cell Biology, 2008, 181, 551-565.	5.2	222
12	Role of voltage-gated calcium channels in ascending pain pathways. Brain Research Reviews, 2009, 60, 84-89.	9.0	215
13	The $\text{Cav}\hat{I}^2$ subunit prevents RFP2-mediated ubiquitination and proteasomal degradation of L-type channels. Nature Neuroscience, 2011, 14, 173-180.	14.8	213
14	$A\hat{l}^2$ neurotoxicity depends on interactions between copper ions, prion protein, and <i>N</i> -methyl- <scp>d</scp> -aspartate receptors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 1737-1742.	7.1	209
15	The Deubiquitinating Enzyme USP5 Modulates Neuropathic and Inflammatory Pain by Enhancing Cav3.2 Channel Activity. Neuron, 2014, 83, 1144-1158.	8.1	197
16	Modulation of voltage-dependent calcium channels by G proteins. Current Opinion in Neurobiology, 1998, 8, 351-356.	4.2	195
17	Depolarization-Induced Ca2+ Release in Ischemic Spinal Cord White Matter Involves L-type Ca2+ Channel Activation of Ryanodine Receptors. Neuron, 2003, 40, 53-63.	8.1	188
18	Extended spectrum of idiopathic generalized epilepsies associated with <i>CACNA1H</i> functional variants. Annals of Neurology, 2007, 62, 560-568.	5 . 3	186

#	Article	IF	CITATIONS
19	Role of Prelimbic GABAergic Circuits in Sensory and Emotional Aspects of Neuropathic Pain. Cell Reports, 2015, 12, 752-759.	6.4	186
20	A neuronal circuit for activating descending modulation of neuropathic pain. Nature Neuroscience, 2019, 22, 1659-1668.	14.8	185
21	The CACNA1F Gene Encodes an L-Type Calcium Channel with Unique Biophysical Properties and Tissue Distribution. Journal of Neuroscience, 2004, 24, 1707-1718.	3.6	183
22	Specific T-type calcium channel isoforms are associated with distinct burst phenotypes in deep cerebellar nuclear neurons. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5555-5560.	7.1	181
23	Voltage-Gated Calcium Channels and Idiopathic Generalized Epilepsies. Physiological Reviews, 2006, 86, 941-966.	28.8	169
24	CaV3 T-type calcium channel isoforms differentially distribute to somatic and dendritic compartments in rat central neurons. European Journal of Neuroscience, 2006, 24, 2581-2594.	2.6	167
25	Regulation of CaV2 calcium channels by G protein coupled receptors. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 1629-1643.	2.6	165
26	Regulation of neuronal activity by Cav3-Kv4 channel signaling complexes. Nature Neuroscience, 2010, 13, 333-337.	14.8	162
27	Gating Effects of Mutations in the Cav3.2 T-type Calcium Channel Associated with Childhood Absence Epilepsy. Journal of Biological Chemistry, 2004, 279, 9681-9684.	3.4	155
28	Trigeminal neuralgia: An overview from pathophysiology to pharmacological treatments. Molecular Pain, 2020, 16, 174480692090189.	2.1	153
29	ORL1 receptor–mediated internalization of N-type calcium channels. Nature Neuroscience, 2006, 9, 31-40.	14.8	151
30	The \hat{l}_{\pm} sub>1ECalcium Channel Exhibits Permeation Properties Similar to Low-Voltage-Activated Calcium Channels. Journal of Neuroscience, 1996, 16, 4983-4993.	3.6	150
31	Role of voltage-gated calcium channels in epilepsy. Pflugers Archiv European Journal of Physiology, 2010, 460, 395-403.	2.8	149
32	Differential Role of N-Type Calcium Channel Splice Isoforms in Pain. Journal of Neuroscience, 2007, 27, 6363-6373.	3.6	147
33	Transient Receptor Potential Vanilloid-4 Has a Major Role in Visceral Hypersensitivity Symptoms. Gastroenterology, 2008, 135, 937-946.e2.	1.3	146
34	Regulation of neuronal T-type calcium channels. Trends in Pharmacological Sciences, 2009, 30, 32-40.	8.7	145
35	Targeting Ca channels to treat pain: T-type versus N-type. Trends in Pharmacological Sciences, 2004, 25, 465-470.	8.7	138
36	Interaction of SNX482 with Domains III and IV Inhibits Activation Gating of $\hat{l}\pm 1E$ (CaV2.3) Calcium Channels. Biophysical Journal, 2001, 81, 79-88.	0.5	136

#	Article	IF	Citations
37	Interactions between presynaptic Ca2+ channels, cytoplasmic messengers and proteins of the synaptic vesicle release complex. Trends in Pharmacological Sciences, 2001, 22, 519-525.	8.7	132
38	Potentiation of TRPV4 signalling by histamine and serotonin: an important mechanism for visceral hypersensitivity. Gut, 2010, 59, 481-488.	12.1	130
39	Blocking microglial pannexin-1 channels alleviates morphine withdrawal in rodents. Nature Medicine, 2017, 23, 355-360.	30.7	130
40	Agonist-independent modulation of N-type calcium channels by ORL1 receptors. Nature Neuroscience, 2004, 7, 118-125.	14.8	128
41	Presynaptic Ca2+ channels – integration centers for neuronal signaling pathways. Trends in Neurosciences, 2006, 29, 617-624.	8.6	128
42	G Protein Modulation of N-type Calcium Channels Is Facilitated by Physical Interactions between Syntaxin 1A and $\hat{Gl^2l^3}$. Journal of Biological Chemistry, 2000, 275, 6388-6394.	3.4	126
43	Identification of an Integration Center for Cross-talk between Protein Kinase C and G Protein Modulation of N-type Calcium Channels. Journal of Biological Chemistry, 1999, 274, 6195-6202.	3.4	120
44	Expression of voltage-gated Ca2+ channel subtypes in cultured astrocytes. Glia, 2003, 41, 347-353.	4.9	119
45	Integrin Receptor Activation Triggers Converging Regulation of Cav1.2 Calcium Channels by c-Src and Protein Kinase A Pathways. Journal of Biological Chemistry, 2006, 281, 14015-14025.	3.4	119
46	Trafficking of L-type Calcium Channels Mediated by the Postsynaptic Scaffolding Protein AKAP79. Journal of Biological Chemistry, 2002, 277, 33598-33603.	3.4	118
47	Auxiliary subunit regulation of high-voltage activated calcium channels expressed in mammalian cells. European Journal of Neuroscience, 2004, 20, 1-13.	2.6	117
48	Cysteine String Protein Regulates G Protein Modulation of N-Type Calcium Channels. Neuron, 2000, 28, 195-204.	8.1	114
49	Effects of Cav3.2 channel mutations linked to idiopathic generalized epilepsy. Annals of Neurology, 2005, 57, 745-749.	5.3	110
50	A Cav3.2/Syntaxin-1A Signaling Complex Controls T-type Channel Activity and Low-threshold Exocytosis. Journal of Biological Chemistry, 2012, 287, 2810-2818.	3.4	110
51	Functional interactions between presynaptic calcium channels and the neurotransmitter release machinery. Current Opinion in Neurobiology, 2003, 13, 308-314.	4.2	108
52	Binding of Protein Phosphatase 2A to the L-Type Calcium Channel Cav1.2 next to Ser1928, Its Main PKA Site, Is Critical for Ser1928 Dephosphorylation. Biochemistry, 2006, 45, 3448-3459.	2.5	106
53	Functional roles of cytoplasmic loops and pore lining transmembrane helices in the voltage-dependent inactivation of HVA calcium channels. Journal of Physiology, 2004, 554, 263-273.	2.9	101
54	D1 Receptors Physically Interact with N-Type Calcium Channels to Regulate Channel Distribution and Dendritic Calcium Entry. Neuron, 2008, 58, 557-570.	8.1	101

#	Article	IF	Citations
55	Glutamate receptors on myelinated spinal cord axons: I. GluR6 kainate receptors. Annals of Neurology, 2009, 65, 151-159.	5.3	100
56	Interactions between a Pore-Blocking Peptide and the Voltage Sensor of the Sodium Channel: An Electrostatic Approach to Channel Geometry. Neuron, 1996, 16, 407-413.	8.1	98
57	Distinct Molecular Determinants Govern Syntaxin 1A-Mediated Inactivation and G-Protein Inhibition of N-Type Calcium Channels. Journal of Neuroscience, 2001, 21, 2939-2948.	3.6	97
58	Regulation of Presynaptic Calcium Channels by Synaptic Proteins. Journal of Pharmacological Sciences, 2003, 92, 79-83.	2.5	97
59	Glutamate receptors on myelinated spinal cord axons: II. AMPA and GluR5 receptors. Annals of Neurology, 2009, 65, 160-166.	5.3	97
60	Recent advances in the development of Tâ€type calcium channel blockers for pain intervention. British Journal of Pharmacology, 2018, 175, 2375-2383.	5.4	93
61	Fast Inactivation of Voltage-dependent Calcium Channels. Journal of Biological Chemistry, 2000, 275, 24575-24582.	3.4	92
62	Surface expression and function of Cav3.2ÂT-type calcium channels are controlled by asparagine-linked glycosylation. Pflugers Archiv European Journal of Physiology, 2013, 465, 1159-1170.	2.8	92
63	Copperâ€dependent regulation of NMDA receptors by cellular prion protein: implications for neurodegenerative disorders. Journal of Physiology, 2012, 590, 1357-1368.	2.9	91
64	Molecular Determinants of Syntaxin 1 Modulation of N-type Calcium Channels. Journal of Biological Chemistry, 2002, 277, 44399-44407.	3.4	89
65	Synthesis and Evaluation of a New Class of Nifedipine Analogs with T-Type Calcium Channel Blocking Activity. Molecular Pharmacology, 2002, 61, 649-658.	2.3	88
66	Calcium Channel Structural Determinants of Synaptic Transmission between Identified Invertebrate Neurons. Journal of Biological Chemistry, 2003, 278, 4258-4267.	3.4	88
67	Residue Gly1326 of the N-type Calcium Channel $\hat{l}\pm 1B$ Subunit Controls Reversibility of $i\%$ -Conotoxin GVIA and MVIIA Block. Journal of Biological Chemistry, 2001, 276, 15728-15735.	3.4	87
68	De Novo Pathogenic Variants in CACNA1E Cause Developmental and Epileptic Encephalopathy with Contractures, Macrocephaly, and Dyskinesias. American Journal of Human Genetics, 2018, 103, 666-678.	6.2	87
69	Determinants of Inhibition of Transiently Expressed Voltage-gated Calcium Channels by ï‰-Conotoxins GVIA and MVIIA. Journal of Biological Chemistry, 2003, 278, 20171-20178.	3.4	86
70	Excitatory Glycine Responses of CNS Myelin Mediated by NR1/NR3 "NMDA―Receptor Subunits. Journal of Neuroscience, 2010, 30, 11501-11505.	3.6	86
71	Intermediate conductance calcium-activated potassium channels modulate summation of parallel fiber input in cerebellar Purkinje cells. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2601-2606.	7.1	85
72	Regulation of T-type calcium channels by Rho-associated kinase. Nature Neuroscience, 2007, 10, 854-860.	14.8	84

#	Article	IF	Citations
73	Expression of T-type calcium channel splice variants in human glioma. Glia, 2004, 48, 112-119.	4.9	83
74	Mercury-induced toxicity of rat cortical neurons is mediated through N-methyl-D-Aspartate receptors. Molecular Brain, 2012, 5, 30.	2.6	82
75	Topiramate Inhibits the Initiation of Plateau Potentials in CA1 Neurons by Depressing R-type Calcium Channels. Epilepsia, 2005, 46, 481-489.	5.1	81
76	Neuroprotection against Traumatic Brain Injury by a Peptide Derived from the Collapsin Response Mediator Protein 2 (CRMP2). Journal of Biological Chemistry, 2011, 286, 37778-37792.	3.4	78
77	Heterodimerization of ORL1 and Opioid Receptors and Its Consequences for N-type Calcium Channel Regulation. Journal of Biological Chemistry, 2010, 285, 1032-1040.	3.4	77
78	The $\hat{l}\pm2\hat{l}'$ Auxiliary Subunit Reduces Affinity of \ddot{l} %-Conotoxins for Recombinant N-type (Cav2.2) Calcium Channels. Journal of Biological Chemistry, 2004, 279, 34705-34714.	3.4	74
79	Microglial pannexin-1 channel activation is a spinal determinant of joint pain. Science Advances, 2018, 4, eaas9846.	10.3	73
80	T-type calcium channels: From molecule to therapeutic opportunities. International Journal of Biochemistry and Cell Biology, 2019, 108, 34-39.	2.8	73
81	Identification and Characterization of Novel Human Cav2.2 ($\hat{l}\pm 1B$) Calcium Channel Variants Lacking the Synaptic Protein Interaction Site. Journal of Neuroscience, 2002, 22, 82-92.	3.6	70
82	Trafficking and regulation of neuronal voltage-gated calcium channels. Current Opinion in Cell Biology, 2007, 19, 474-482.	5.4	69
83	Trafficking and stability of voltage-gated calcium channels. Cellular and Molecular Life Sciences, 2012, 69, 843-856.	5.4	69
84	Small Organic Molecule Disruptors of Cav3.2 - USP5 Interactions Reverse Inflammatory and Neuropathic Pain. Molecular Pain, 2015, 11 , $12990-015-0011$.	2.1	69
85	Molecular Pharmacology of High Voltage-Activated Calcium Channels. Journal of Bioenergetics and Biomembranes, 2003, 35, 491-505.	2.3	65
86	Functional Analysis of Cav3.2 T-type Calcium Channel Mutations Linked to Childhood Absence Epilepsy. Epilepsia, 2006, 47, 655-658.	5.1	64
87	Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6467-6472.	2.2	64
88	IKCa Channels Are a Critical Determinant of the Slow AHP in CA1 Pyramidal Neurons. Cell Reports, 2015, 11, 175-182.	6.4	64
89	Unique Structureâ^'Activity Relationship for 4-Isoxazolyl-1,4-dihydropyridines. Journal of Medicinal Chemistry, 2003, 46, 87-96.	6.4	62
90	Anticonvulsant mechanisms of piperine, a piperidine alkaloid. Channels, 2015, 9, 317-323.	2.8	62

#	Article	IF	CITATIONS
91	Differential modulation of Nâ€type α 1B and P/Qâ€type α 1A calcium channels by different G protein β subunit isoforms. Journal of Physiology, 2000, 527, 203-212.	2.9	61
92	Scanning Mutagenesis of ω-Atracotoxin-Hv1a Reveals a Spatially Restricted Epitope That Confers Selective Activity against Insect Calcium Channels. Journal of Biological Chemistry, 2004, 279, 44133-44140.	3.4	61
93	Cross-talk between G-protein and Protein Kinase C Modulation of N-type Calcium Channels Is Dependent on the G-protein β Subunit Isoform. Journal of Biological Chemistry, 2000, 275, 40777-40781.	3.4	59
94	A novel slow-inactivation-specific ion channel modulator attenuates neuropathic pain. Pain, 2011, 152, 833-843.	4.2	59
95	Glutamate receptors function as scaffolds for the regulation of \hat{l}^2 -amyloid and cellular prion protein signaling complexes. Molecular Brain, 2015, 8, 18.	2.6	59
96	Calcium Channel \hat{l}^2 Subunits Differentially Regulate the Inhibition of N-type Channels by Individual G \hat{l}^2 Isoforms. Journal of Biological Chemistry, 2001, 276, 45051-45058.	3.4	56
97	Block of voltage-gated calcium channels by peptide toxins. Neuropharmacology, 2017, 127, 109-115.	4.1	55
98	Cellular prion protein and NMDA receptor modulation: protecting against excitotoxicity. Frontiers in Cell and Developmental Biology, 2014, 2, 45.	3.7	54
99	Possible role of trace elements in epilepsy and febrile seizures: a meta-analysis. Nutrition Reviews, 2015, 73, 760-779.	5.8	54
100	T-Type Calcium Channel $\hat{l}\pm 1G$ and $\hat{l}\pm 1H$ Subunits in Human Retinoblastoma Cells and Their Loss After Differentiation. Journal of Neurophysiology, 2002, 88, 196-205.	1.8	53
101	Control of low-threshold exocytosis by T-type calcium channels. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 1579-1586.	2.6	53
102	Synthesis and Evaluation of 1,4-Dihydropyridine Derivatives with Calcium Channel Blocking Activity. Pflugers Archiv European Journal of Physiology, 2014, 466, 1355-1363.	2.8	53
103	Identification of Inactivation Determinants in the Domain IIS6 Region of High Voltage-activated Calcium Channels. Journal of Biological Chemistry, 2001, 276, 33001-33010.	3.4	52
104	Syntaxin 1A Supports Voltage-Dependent Inhibition of $\hat{l}\pm 1BCa2+Channels$ by $G\hat{l}^2\hat{l}^3$ in Chick Sensory Neurons. Journal of Neuroscience, 2001, 21, 2949-2957.	3.6	51
105	Glycerotoxin from Glycera convoluta stimulates neurosecretion by up-regulating N-type Ca2+channel activity. EMBO Journal, 2002, 21, 6733-6743.	7.8	51
106	Masters or slaves? Vesicle release machinery and the regulation of presynaptic calcium channels. Cell Calcium, 2005, 37, 483-488.	2.4	51
107	D2 dopamine receptors interact directly with N-type calcium channels and regulate channel surface expression levels. Channels, 2008, 2, 269-277.	2.8	51
108	Genetic T-type calcium channelopathies. Journal of Medical Genetics, 2020, 57, 1-10.	3.2	50

#	Article	IF	Citations
109	Role of the synprint site in presynaptic targeting of the calcium channel Ca V 2.2 in hippocampal neurons. European Journal of Neuroscience, 2006, 24, 709-718.	2.6	49
110	Crosstalk between huntingtin and syntaxin 1A regulates N-type calcium channels. Molecular and Cellular Neurosciences, 2005, 30, 339-351.	2.2	48
111	Low Voltage Activation of KCa1.1 Current by Cav3-KCa1.1 Complexes. PLoS ONE, 2013, 8, e61844.	2.5	48
112	Selective inhibition of Ca $<$ sub $>$ V $<$ /sub $>$ 3.2 channels reverses hyperexcitability of peripheral nociceptors and alleviates postsurgical pain. Science Signaling, 2018, 11, .	3.6	48
113	Modulation of Neuronal Voltage-gated Calcium Channels by Farnesol. Journal of Biological Chemistry, 1999, 274, 25439-25446.	3.4	47
114	Calcium-triggered Membrane Fusion Proceeds Independently of Specific Presynaptic Proteins. Journal of Biological Chemistry, 2003, 278, 24251-24254.	3.4	47
115	Dopamine Inputs from the Ventral Tegmental Area into the Medial Prefrontal Cortex Modulate Neuropathic Pain-Associated Behaviors in Mice. Cell Reports, 2020, 31, 107812.	6.4	47
116	Determinants of G Protein Inhibition of Presynaptic Calcium Channels. Cell Biochemistry and Biophysics, 2001, 34, 79-84.	1.8	46
117	Kainate receptor activation induces glycine receptor endocytosis through PKC deSUMOylation. Nature Communications, 2014, 5, 4980.	12.8	46
118	Antagonist binding sites of voltage-dependent calcium channels. Drug Development Research, 1997, 42, 131-143.	2.9	45
119	Amino Acid Residues Outside of the Pore Region Contribute to N-type Calcium Channel Permeation. Journal of Biological Chemistry, 2001, 276, 5726-5730.	3.4	45
120	Cysteine String Protein (CSP) Inhibition of N-type Calcium Channels Is Blocked by Mutant Huntingtin. Journal of Biological Chemistry, 2003, 278, 53072-53081.	3.4	45
121	BK Potassium Channels Suppress $Cavl^{\pm}2l^{2}$ Subunit Function to Reduce Inflammatory and Neuropathic Pain. Cell Reports, 2018, 22, 1956-1964.	6.4	45
122	Junctophilin Proteins Tether a Cav1-RyR2-KCa3.1 Tripartite Complex to Regulate Neuronal Excitability. Cell Reports, 2019, 28, 2427-2442.e6.	6.4	45
123	Cav3.2 T-type calcium channels shape electrical firing in mouse Lamina II neurons. Scientific Reports, 2019, 9, 3112.	3.3	45
124	Voltage Gated Calcium Channels as Targets for Analgesics. Current Topics in Medicinal Chemistry, 2005, 5, 539-546.	2.1	44
125	The Ca _v 3–K _v 4 Complex Acts as a Calcium Sensor to Maintain Inhibitory Charge Transfer during Extracellular Calcium Fluctuations. Journal of Neuroscience, 2013, 33, 7811-7824.	3.6	44
126	A Membrane Potential- and Calpain-Dependent Reversal of Caspase-1 Inhibition Regulates Canonical NLRP3 Inflammasome. Cell Reports, 2018, 24, 2356-2369.e5.	6.4	44

#	Article	IF	CITATIONS
127	Betulinic acid, derived from the desert lavender Hyptis emoryi, attenuates paclitaxel-, HIV-, and nerve injury–associated peripheral sensory neuropathy via block of N- and T-type calcium channels. Pain, 2019, 160, 117-135.	4.2	44
128	Structure–activity relationships of diphenylpiperazine N-type calcium channel inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1378-1383.	2.2	43
129	RIM1/2-Mediated Facilitation of Cav1.4 Channel Opening Is Required for Ca ²⁺ -Stimulated Release in Mouse Rod Photoreceptors. Journal of Neuroscience, 2015, 35, 13133-13147.	3.6	43
130	Selective Inhibition of Cav3.3 T-type Calcium Channels by $\hat{Gl} \pm q/11$ -coupled Muscarinic Acetylcholine Receptors. Journal of Biological Chemistry, 2007, 282, 21043-21055.	3.4	42
131	Characterization of Novel Cannabinoid Based T-Type Calcium Channel Blockers with Analgesic Effects. ACS Chemical Neuroscience, 2015, 6, 277-287.	3.5	42
132	Protein interactome mining defines melatonin <scp>MT</scp> ₁ receptors as integral component of presynaptic protein complexes of neurons. Journal of Pineal Research, 2016, 60, 95-108.	7.4	42
133	Depressive-like behaviour of mice lacking cellular prion protein. Behavioural Brain Research, 2012, 227, 319-323.	2.2	40
134	1,4-Dihydropyridine derivatives with T-type calcium channel blocking activity attenuate inflammatory and neuropathic pain. Pflugers Archiv European Journal of Physiology, 2015, 467, 1237-1247.	2.8	40
135	Multiple Structural Domains Contribute to Voltage-dependent Inactivation of Rat Brain $\hat{l}\pm 1E$ Calcium Channels. Journal of Biological Chemistry, 1999, 274, 22428-22436.	3.4	39
136	Molecular determinants of cysteine string protein modulation of N-type calcium channels. Journal of Cell Science, 2003, 116, 2967-2974.	2.0	39
137	A cell-permeant peptide corresponding to the cUBP domain of USP5 reverses inflammatory and neuropathic pain. Molecular Pain, 2016, 12, 174480691664244.	2.1	39
138	Identification of interleukin-1 beta as a key mediator in the upregulation of Cav3.2–USP5 interactions in the pain pathway. Molecular Pain, 2017, 13, 174480691772469.	2.1	39
139	Inhibition of Neuronal Calcium Channels by a Novel Peptide Spider Toxin, DW13.3. Molecular Pharmacology, 1998, 54, 407-418.	2.3	38
140	Signaling complexes of voltage-gated calcium channels. Channels, 2011, 5, 440-448.	2.8	38
141	Regulation of the K _V 4.2 complex by Ca _V 3.1 calcium channels. Channels, 2010, 4, 163-167.	2.8	37
142	Block of T-type calcium channels by protoxins I and II. Molecular Brain, 2014, 7, 36.	2.6	37
143	In Vitro Characterization of L-Type Calcium Channels and Their Contribution to Firing Behavior in Invertebrate Respiratory Neurons. Journal of Neurophysiology, 2006, 95, 42-52.	1.8	36
144	Analgesic Effect of a Mixed T-Type Channel Inhibitor/CB ₂ Receptor Agonist. Molecular Pain, 2013, 9, 1744-8069-9-32.	2.1	36

#	Article	IF	CITATIONS
145	T-type channels buddy up. Pflugers Archiv European Journal of Physiology, 2014, 466, 661-675.	2.8	35
146	Neuronal expression of the intermediate conductance calcium-activated potassium channel KCa3.1 in the mammalian central nervous system. Pflugers Archiv European Journal of Physiology, 2015, 467, 311-328.	2.8	35
147	The Cacna1h mutation in the GAERS model of absence epilepsy enhances T-type Ca2+ currents by altering calnexin-dependent trafficking of Cav3.2 channels. Scientific Reports, 2017, 7, 11513.	3.3	35
148	Regulation of voltage gated calcium channels by GPCRs and post-translational modification. Current Opinion in Pharmacology, 2017, 32, 1-8.	3. 5	35
149	Binding mechanism investigations guiding the synthesis of novel condensed 1,4-dihydropyridine derivatives with L-/T-type calcium channel blocking activity. European Journal of Medicinal Chemistry, 2018, 155, 1-12.	5 . 5	34
150	Expression and Modulation of an Invertebrate Presynaptic Calcium Channel $\hat{l}\pm 1$ Subunit Homolog. Journal of Biological Chemistry, 2003, 278, 21178-21187.	3.4	33
151	Cav1.4 Encodes a Calcium Channel with Low Open Probability and Unitary Conductance. Biophysical Journal, 2005, 89, 3042-3048.	0.5	33
152	Analgesic effect of a broad-spectrum dihydropyridine inhibitor of voltage-gated calcium channels. Pflugers Archiv European Journal of Physiology, 2015, 467, 2485-2493.	2.8	33
153	The Third Intracellular Loop Stabilizes the Inactive State of the Neuropeptide Y1 Receptor. Journal of Biological Chemistry, 2008, 283, 33337-33346.	3.4	32
154	NMP-7 Inhibits Chronic Inflammatory and Neuropathic Pain via Block of Cav3.2 T-type Calcium Channels and Activation of CB2 Receptors. Molecular Pain, 2014, 10, 1744-8069-10-77.	2.1	32
155	Signaling Complexes of Voltage-Gated Calcium Channels and G Protein-Coupled Receptors. Journal of Receptor and Signal Transduction Research, 2008, 28, 71-81.	2.5	31
156	Regulation of calcium channels by RGK proteins. Channels, 2010, 4, 434-439.	2.8	31
157	Functional Characterization and Analgesic Effects of Mixed Cannabinoid Receptor/T-Type Channel Ligands. Molecular Pain, 2011, 7, 1744-8069-7-89.	2.1	31
158	T-type calcium channels functionally interact with spectrin $(\hat{l}\pm\hat{l}^2)$ and ankyrin B. Molecular Brain, 2018, 11, 24.	2.6	31
159	A Single GÎ ² Subunit Locus Controls Cross-talk between Protein Kinase C and G Protein Regulation of N-type Calcium Channels. Journal of Biological Chemistry, 2004, 279, 29709-29717.	3.4	30
160	Spatial association of the Cav1.2 calcium channel with \hat{l}_{\pm} (sub>5 \hat{l}^{2} (sub>1-integrin. American Journal of Physiology - Cell Physiology, 2011, 300, C477-C489.	4.6	30
161	Disruption of NMDAR–CRMP-2 signaling protects against focal cerebral ischemic damage in the rat middle cerebral artery occlusion model. Channels, 2012, 6, 52-59.	2.8	30
162	Activity-Dependent Facilitation of Ca _V 1.3 Calcium Channels Promotes KCa3.1 Activation in Hippocampal Neurons. Journal of Neuroscience, 2017, 37, 11255-11270.	3.6	30

#	Article	IF	Citations
163	Hyperactivity of Innate Immunity Triggers Pain via TLR2-IL-33-Mediated Neuroimmune Crosstalk. Cell Reports, 2020, 33, 108233.	6.4	29
164	Prion protein attenuates excitotoxicity by inhibiting NMDA receptors. Journal of General Physiology, 2008, 131, i5-i5.	1.9	29
165	Presynaptic Calcium Channels: Structure, Regulators, and Blockers. Handbook of Experimental Pharmacology, 2008, , 45-75.	1.8	28
166	Common Mechanisms of Drug Interactions with Sodium and T-Type Calcium Channels. Molecular Pharmacology, 2012, 82, 481-487.	2.3	28
167	The Expression Pattern of a Cav3-Kv4 Complex Differentially Regulates Spike Output in Cerebellar Granule Cells. Journal of Neuroscience, 2014, 34, 8800-8812.	3.6	28
168	T-Type Channel Druggability at a Crossroads. ACS Chemical Neuroscience, 2019, 10, 1124-1126.	3.5	28
169	Central and peripheral contributions of T-type calcium channels in pain. Molecular Brain, 2022, 15, 39.	2.6	27
170	Cellular Prion Protein Protects from Inflammatory and Neuropathic Pain. Molecular Pain, 2011, 7, 1744-8069-7-59.	2.1	26
171	Cooperative roles of glucose and asparagine-linked glycosylation in T-type calcium channel expression. Pflugers Archiv European Journal of Physiology, 2016, 468, 1837-1851.	2.8	26
172	Synthesis and biological evaluation of novel N3- substituted dihydropyrimidine derivatives as T-type calcium channel blockers and their efficacy as analgesics in mouse models of inflammatory pain. Bioorganic and Medicinal Chemistry, 2017, 25, 1926-1938.	3.0	26
173	Peripheral nerve injury-induced alterations in VTA neuron firing properties. Molecular Brain, 2019, 12, 89.	2.6	26
174	A novel calmodulin site in the Cav1.2 N-terminus regulates calcium-dependent inactivation. Pflugers Archiv European Journal of Physiology, 2014, 466, 1793-1803.	2.8	25
175	Block of Voltage-Dependent Calcium Channels by Aliphatic Monoamines. Biophysical Journal, 2000, 79, 260-270.	0.5	24
176	Regulation of Voltage-Gated Calcium Channels by Synaptic Proteins. Advances in Experimental Medicine and Biology, 2012, 740, 759-775.	1.6	24
177	Structure–activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4153-4158.	2.2	24
178	N-type Ca2+ channels are affected by full-length mutant huntingtin expression in a mouse model of Huntington's disease. Neurobiology of Aging, 2017, 55, 1-10.	3.1	24
179	Anxiolytic effects of the flavonoid luteolin in a mouse model of acute colitis. Molecular Brain, 2019, 12, 114.	2.6	24
180	Uncoupling of Calcium Channel $\hat{l}\pm 1$ and \hat{l}^2 Subunits in Developing Neurons. Journal of Biological Chemistry, 2004, 279, 41157-41167.	3.4	23

#	Article	IF	Citations
181	Effect of the T-type channel blocker KYS-05090S in mouse models of acute and neuropathic pain. Pflugers Archiv European Journal of Physiology, 2016, 468, 193-199.	2.8	23
182	TNF- $\hat{l}\pm$ mediated upregulation of NaV1.7 currents in rat dorsal root ganglion neurons is independent of CRMP2 SUMOylation. Molecular Brain, 2019, 12, 117.	2.6	23
183	Voltageâ€gated calcium channel nanodomains: molecular composition and function. FEBS Journal, 2022, 289, 614-633.	4.7	23
184	Evidence for a specific site for modulation of calcium channel activation by external calcium ions. Pflugers Archiv European Journal of Physiology, 1996, 431, 470-472.	2.8	22
185	Several Structural Domains Contribute to the Regulation of N-type Calcium Channel Inactivation by the \hat{l}^2 3 Subunit. Journal of Biological Chemistry, 2004, 279, 3793-3800.	3.4	22
186	Novel Splice Variants of Rat CaV2.1 That Lack Much of the Synaptic Protein Interaction Site Are Expressed in Neuroendocrine Cells. Journal of Biological Chemistry, 2008, 283, 15997-16003.	3.4	22
187	Assessing the role of IKCa channels in generating the sAHP of CA1 hippocampal pyramidal cells. Channels, 2016, 10, 313-319.	2.8	22
188	Discovery and mode of action of a novel analgesic \hat{l}^2 -toxin from the African spider Ceratogyrus darlingi. PLoS ONE, 2017, 12, e0182848.	2.5	22
189	A T-type channel-calmodulin complex triggers αCaMKII activation. Molecular Brain, 2017, 10, 37.	2.6	22
190	CaV3.2 calcium channels contribute to trigeminal neuralgia. Pain, 2022, 163, 2315-2325.	4.2	22
191	Trafficking of neuronal calcium channels. Neuronal Signaling, 2017, 1, NS20160003.	3.2	21
192	A potential role for T-type calcium channels in homocysteinemia-induced peripheral neuropathy. Pain, 2019, 160, 2798-2810.	4.2	21
193	Calmodulin Lobotomized. Neuron, 2003, 39, 879-881.	8.1	20
194	Activityâ€driven mobilization of postâ€synaptic proteins. European Journal of Neuroscience, 2009, 30, 2042-2052.	2.6	20
195	Signal processing by T-type calcium channel interactions in the cerebellum. Frontiers in Cellular Neuroscience, 2013, 7, 230.	3.7	20
196	Two heterozygous Cav3.2 channel mutations in a pediatric chronic pain patient: recording condition-dependent biophysical effects. Pflugers Archiv European Journal of Physiology, 2016, 468, 635-642.	2.8	20
197	Differential modulation of NMDA and AMPA receptors by cellular prion protein and copper ions. Molecular Brain, $2018,11,62.$	2.6	20
198	Dopaminergic modulation of pain signals in the medial prefrontal cortex: Challenges and perspectives. Neuroscience Letters, 2019, 702, 71-76.	2.1	20

#	Article	IF	Citations
199	Molecular Pharmacology of Non-L-type Calcium Channels. Current Pharmaceutical Design, 2005, 11, 1887-1898.	1.9	19
200	Voltage-Gated Sodium and Calcium Channels in Nerve, Muscle, and Heart. IEEE Transactions on Nanobioscience, 2005, 4, 58-69.	3.3	19
201	Opioid, cheating on its receptors, exacerbates pain. Nature Neuroscience, 2006, 9, 1465-1467.	14.8	19
202	Molecular determinants of Rem2 regulation of N-type calcium channels. Biochemical and Biophysical Research Communications, 2008, 368, 827-831.	2.1	19
203	Differential Interactions of Na+ Channel Toxins with T-type Ca2+ Channels. Journal of General Physiology, 2008, 132, 101-113.	1.9	19
204	CCR2 Receptor Ligands Inhibit Cav3.2 T-Type Calcium Channels. Molecular Pharmacology, 2010, 77, 211-217.	2.3	19
205	How do T-type calcium channels control low-threshold exocytosis?. Communicative and Integrative Biology, 2012, 5, 377-380.	1.4	19
206	CaV2.2 channel cell surface expression is regulated by the light chain 1 (LC1) of the microtubule-associated protein B (MAP1B) via UBE2L3-mediated ubiquitination and degradation. Pflugers Archiv European Journal of Physiology, 2014, 466, 2113-2126.	2.8	19
207	Neuroimmune Responses Mediate Depression-Related Behaviors following Acute Colitis. IScience, 2019, 16, 12-21.	4.1	19
208	Design, synthesis and pharmacological evaluation of some substituted dihydropyrimidines with L-/T-type calcium channel blocking activities. Bioorganic Chemistry, 2019, 83, 354-366.	4.1	19
209	Acute orofacial pain leads to prolonged changes in behavioral and affective pain components. Pain, 2020, 161, 2830-2840.	4.2	19
210	FMRP(1–297)-tat restores ion channel and synaptic function in a model of Fragile X syndrome. Nature Communications, 2020, 11, 2755.	12.8	19
211	A Minimal Model for G Protein–Mediated Synaptic Facilitation and Depression. Journal of Neurophysiology, 2003, 90, 1643-1653.	1.8	18
212	Bipartite syntaxin 1A interactions mediate CaV2.2 calcium channel regulation. Biochemical and Biophysical Research Communications, 2011, 411, 562-568.	2.1	18
213	The Immediately Releasable Pool of Mouse Chromaffin Cell Vesicles Is Coupled to P/Q-Type Calcium Channels via the Synaptic Protein Interaction Site. PLoS ONE, 2013, 8, e54846.	2.5	18
214	Old proteins, developing roles: The regulation of calcium channels by synaptic proteins. Channels, 2008, 2, 130-138.	2.8	17
215	SUMOylation regulates USP5-Cav3.2 calcium channel interactions. Molecular Brain, 2019, 12, 73.	2.6	17
216	Gut-innervating TRPV1+ Neurons Drive Chronic Visceral Pain via Microglial P2Y12 Receptor. Cellular and Molecular Gastroenterology and Hepatology, 2022, 13, 977-999.	4.5	17

#	Article	IF	CITATIONS
217	Glycerotoxin stimulates neurotransmitter release from N-type Ca2+ channel expressing neurons. Journal of Neurochemistry, 2006, 98, 894-904.	3.9	16
218	Calcium Channel Signaling Complexes with Receptors and Channels. Current Molecular Pharmacology, 2015, 8, 8-11.	1.5	16
219	Long-Term Potentiation at the Mossy Fiber–Granule Cell Relay Invokes Postsynaptic Second-Messenger Regulation of Kv4 Channels. Journal of Neuroscience, 2016, 36, 11196-11207.	3.6	16
220	Synthesis of new N3- substituted dihydropyrimidine derivatives as L-/T- type calcium channel blockers. European Journal of Medicinal Chemistry, 2017, 134, 52-61.	5 . 5	16
221	Discovery of Michael acceptor containing $1,4$ -dihydropyridines as first covalent inhibitors of L-/T-type calcium channels. Bioorganic Chemistry, 2019, 91, 103187.	4.1	16
222	Modulating Modulation: Crosstalk Between Regulatory Pathways of Presynaptic Calcium Channels. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2002, 2, 476-478.	3.4	16
223	Activity-Dependent Subcellular Cotrafficking of the Small GTPase Rem2 and Ca2+/CaM-Dependent Protein Kinase Ill ±. PLoS ONE, 2012, 7, e41185.	2,5	16
224	The terpenes camphene and alpha-bisabolol inhibit inflammatory and neuropathic pain via Cav3.2ÂT-type calcium channels. Molecular Brain, 2021, 14, 166.	2.6	16
225	Linking calcium-channel isoforms to potential therapies. Current Opinion in Investigational Drugs, 2008, 9, 707-15.	2.3	16
226	The Arg473Cys-neuroligin-1 mutation modulates NMDA mediated synaptic transmission and receptor distribution in hippocampal neurons. FEBS Letters, 2005, 579, 6587-6594.	2.8	15
227	Role of Angiotensin II Type 1A Receptor Phosphorylation, Phospholipase D, and Extracellular Calcium in Isoform-specific Protein Kinase C Membrane Translocation Responses. Journal of Biological Chemistry, 2006, 281, 26340-26349.	3.4	15
228	Role of prions in neuroprotection and neurodegeneration. Prion, 2009, 3, 187-189.	1.8	15
229	L-type calcium channel \hat{l}^2 subunit modulates angiotensin II responses in cardiomyocytes. Channels, 2011, 5, 280-286.	2.8	15
230	Calcium channels as therapeutic targets. Environmental Sciences Europe, 2012, 1, 433-451.	5.5	15
231	Modeling interactions between voltage-gated Ca ²⁺ channels and KCa1.1 channels. Channels, 2013, 7, 524-529.	2.8	15
232	A molecular complex of Ca _v 1.2/CaMKK2/CaMK1a in caveolae is responsible for vascular remodeling via excitation–transcription coupling. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2117435119.	7.1	15
233	Scanning Mutagenesis Reveals a Role for Serine 189 of the Heterotrimeric G-Protein Beta 1 Subunit in the Inhibition of N-Type Calcium Channels. Journal of Neurophysiology, 2006, 96, 465-470.	1.8	14
234	Syntaxin 1A is required for normal in utero development. Biochemical and Biophysical Research Communications, 2008, 375, 372-377.	2.1	14

#	Article	IF	CITATIONS
235	Analgesic properties of S100A9 Câ€terminal domain: a mechanism dependent on calcium channel inhibition. Fundamental and Clinical Pharmacology, 2009, 23, 427-438.	1.9	14
236	<i>In vivo</i> expression of Gâ€protein β ₁ γ ₂ dimer in adult mouse skeletal muscle alters Lâ€type calcium current and excitation–contraction coupling. Journal of Physiology, 2010, 588, 2945-2960.	2.9	14
237	AKAP79 modulation of L-type channels involves disruption of intramolecular interactions in the Ca _V 1.2 subunit. Channels, 2012, 6, 157-165.	2.8	14
238	The Cav1.2ÂN terminus contains a CaM kinase site that modulates channel trafficking and function. Pflugers Archiv European Journal of Physiology, 2015, 467, 677-686.	2.8	14
239	Reduced Hyperpolarization-Activated Current Contributes to Enhanced Intrinsic Excitability in Cultured Hippocampal Neurons from PrPâ°'/â^' Mice. Frontiers in Cellular Neuroscience, 2016, 10, 74.	3.7	14
240	Synthesis and characterization of a disubstituted piperazine derivative with T-type channel blocking action and analgesic properties. Molecular Pain, 2016, 12, 174480691664167.	2.1	14
241	Disrupting USP5/Cav3.2 interactions protects female mice from mechanical hypersensitivity during peripheral inflammation. Molecular Brain, 2018, 11, 60.	2.6	14
242	Ankyrin B and Ankyrin B variants differentially modulate intracellular and surface Cav2.1 levels. Molecular Brain, 2019, 12, 75.	2.6	14
243	A rare CACNA1H variant associated with amyotrophic lateral sclerosis causes complete loss of Cav3.2 T-type channel activity. Molecular Brain, 2020, 13, 33.	2.6	14
244	The life cycle of voltage-gated Ca2+ channels in neurons: an update on the trafficking of neuronal calcium channels. Neuronal Signaling, 2021, 5, NS20200095.	3.2	14
245	The Brugada syndrome mutation A39V does not affect surface expression of neuronal rat Cav1.2 channels. Molecular Brain, 2012, 5, 9.	2.6	13
246	The MAP1B-LC1/UBE2L3 complex catalyzes degradation of cell surface Ca $<$ sub $>$ V $<$ /sub $>$ 2.2 channels. Channels, 2014, 8, 452-457.	2.8	13
247	Cav3.2 T-type calcium channels control acute itch in mice. Molecular Brain, 2020, 13, 119.	2.6	13
248	Opioid Receptor Regulation of Neuronal Voltage-Gated Calcium Channels. Cellular and Molecular Neurobiology, 2021, 41, 839-847.	3.3	13
249	Multiple structural elements contribute to voltage-dependent facilitation of neuronal $\hat{l}\pm 1C$ (CaV1.2) L-type calcium channels. Neuropharmacology, 2001, 40, 1050-1057.	4.1	12
250	Splicing It Up. Neuron, 2004, 41, 3-4.	8.1	12
251	Differential regulation of Cav2.2 channel exon 37 variants by alternatively spliced \hat{l} /4-opioid receptors. Molecular Brain, 2019, 12, 98.	2.6	12
252	The de novo CACNA1A pathogenic variant Y1384C associated with hemiplegic migraine, early onset cerebellar atrophy and developmental delay leads to a loss of Cav2.1 channel function. Molecular Brain, 2021, 14, 27.	2.6	12

#	Article	IF	Citations
253	Synthesis and Biological Evaluation of Novel Benzhydrylpiperazine-Coupled Nitrobenzenesulfonamide Hybrids. ACS Omega, 2021, 6, 9731-9740.	3.5	12
254	A Synthetically Accessible Small-Molecule Inhibitor of USP5-Cav3.2 Calcium Channel Interactions with Analgesic Properties. ACS Chemical Neuroscience, 2022, 13, 524-536.	3.5	12
255	Subcellular localization of hippocampal ryanodine receptor 2 and its role in neuronal excitability and memory. Communications Biology, 2022, 5, 183.	4.4	12
256	Scanning mutagenesis of the I-II loop of the Cav2.2 calcium channel identifies residues Arginine 376 and Valine 416 as molecular determinants of voltage dependent G protein inhibition. Molecular Brain, 2010, 3, 6.	2.6	11
257	Effect of the Brugada syndrome mutation A39V on calmodulin regulation of Cav1.2 channels. Molecular Brain, 2014, 7, 34.	2.6	11
258	Down-regulation of T-type Cav3.2 channels by hyperpolarization-activated cyclic nucleotide-gated channel 1 (HCN1): Evidence of a signaling complex. Channels, 2017, 11, 434-443.	2.8	11
259	A Crash Course in Calcium Channels. ACS Chemical Neuroscience, 2017, 8, 2583-2585.	3.5	11
260	Pathogenic Cav3.2 channel mutation in a child with primary generalized epilepsy. Molecular Brain, 2019, 12, 86.	2.6	11
261	Cav3.2 calcium channel interactions with the epithelial sodium channel ENaC. Molecular Brain, 2019, 12, 12.	2.6	11
262	An orbitofrontal cortex to midbrain projection modulates hypersensitivity after peripheral nerve injury. Cell Reports, 2021, 35, 109033.	6.4	11
263	A CACNA1A variant associated with trigeminal neuralgia alters the gating of Cav2.1 channels. Molecular Brain, 2021, 14, 4.	2.6	11
264	Synthesis of some new C2 substituted dihydropyrimidines and their electrophysiological evaluation as L-/T-type calcium channel blockers. Bioorganic Chemistry, 2019, 88, 102915.	4.1	10
265	Cav3.1 overexpression is associated with negative characteristics and prognosis in non-small cell lung cancer. Oncotarget, 2018, 9, 8573-8583.	1.8	10
266	Molecular determinants of opioid analgesia: Modulation of presynaptic calcium channels. Drug Development Research, 2001, 54, 118-128.	2.9	9
267	Cellular prion protein null mice display normal AMPA receptor mediated long term depression. Prion, 2008, 2, 48-50.	1.8	9
268	Analgesic effects of optogenetic inhibition of basolateral amygdala inputs into the prefrontal cortex in nerve injured female mice. Molecular Brain, 2019, 12, 105.	2.6	9
269	Molecular and kinetic determinants of local anaesthetic action on sodium channels. Toxicology Letters, 1998, 100-101, 247-254.	0.8	8
270	Role for G Protein $G\hat{I}^2\hat{I}^3$ Isoform Specificity in Synaptic Signal Processing: A Computational Study. Journal of Neurophysiology, 2002, 87, 2612-2623.	1.8	8

#	Article	IF	Citations
271	Launching Channels: A New Milestone in the Ion Channel Field. Channels, 2007, 1, 1-1.	2.8	8
272	The Tao of IGF-1: Insulin-Like Growth Factor Receptor Activation Increases Pain by Enhancing T-Type Calcium Channel Activity. Science Signaling, 2014, 7, pe23.	3.6	8
273	Synthesis and biological evaluation of fluoro-substituted 3,4-dihydroquinazoline derivatives for cytotoxic and analgesic effects. Bioorganic and Medicinal Chemistry, 2017, 25, 4656-4664.	3.0	8
274	Interactions of Rabconnectin-3 with Cav2 calcium channels. Molecular Brain, 2019, 12, 62.	2.6	8
275	Functional identification of potential non-canonical N-glycosylation sites within Cav3.2ÂT-type calcium channels. Molecular Brain, 2020, 13, 149.	2.6	8
276	Pain: Integration of Sensory and Affective Aspects of Pain. Current Biology, 2020, 30, R393-R395.	3.9	8
277	Identification of a molecular gating determinant within the carboxy terminal region of Cav3.3 T-type channels. Molecular Brain, 2019, 12, 34.	2.6	7
278	Mutation of copper binding sites on cellular prion protein abolishes its inhibitory action on NMDA receptors in mouse hippocampal neurons. Molecular Brain, 2021, 14, 117.	2.6	7
279	Structural optimization, synthesis and in vitro synergistic anticancer activities of combinations of new N3-substituted dihydropyrimidine calcium channel blockers with cisplatin and etoposide. Bioorganic Chemistry, 2021, 115, 105262.	4.1	7
280	Regulation of CaV3.2 channels by the receptor for activated C kinase 1 (Rack-1). Pflugers Archiv European Journal of Physiology, 2022, 474, 447-454.	2.8	7
281	Solution NMR and calorimetric analysis of Rem2 binding to the Ca $<$ sup $>2+sup> channel \hat{l}^24 subunit: a low affinity interaction is required for inhibition of Cav2.1 Ca <sup>2+sup> currents. FASEB Journal, 2015, 29, 1794-1804.$	0.5	6
282	Inhibitory effect of positively charged triazine antagonists of prokineticin receptors on the transient receptor vanilloid type-1 (TRPV1) channel. Pharmacological Research, 2015, 99, 362-369.	7.1	6
283	Modeling temperature- and Cav3 subtype-dependent alterations in T-type calcium channel mediated burst firing. Molecular Brain, 2021, 14, 115.	2.6	6
284	De novo SCN8A and inherited rare CACNA1H variants associated with severe developmental and epileptic encephalopathy. Molecular Brain, 2021, 14, 126.	2.6	6
285	Trigeminal neuropathic pain causes changes in affective processing of pain in rats. Molecular Pain, 2022, 18, 174480692110577.	2.1	6
286	Advances in voltage-gated calcium channel structure, function and physiology. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 1521.	2.6	5
287	Carisbamate blockade of Tâ€type voltageâ€gated calcium channels. Epilepsia, 2017, 58, 617-626.	5.1	5
288	Synthesis and cytotoxic effects of 2-thio-3,4-dihydroquinazoline derivatives as novel T-type calcium channel blockers. Bioorganic and Medicinal Chemistry, 2020, 28, 115491.	3.0	5

#	Article	IF	Citations
289	The IL33 receptor ST2 contributes to mechanical hypersensitivity in mice with neuropathic pain. Molecular Brain, 2021, 14, 35.	2.6	5
290	The L-type calcium channel C-terminus: sparking interest beyond its role in calcium-dependent inactivation. Journal of Physiology, 2003, 552, 333-333.	2.9	5
291	Analysis of GPCR/Ion Channel Interactions. Methods in Molecular Biology, 2011, 756, 215-225.	0.9	4
292	Tuning the regulator: Phosphorylation of KCC2 at two specific sites is critical for neurodevelopment. Science Signaling, 2019, 12, .	3.6	4
293	Putative Synthetic Cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and Their Analogues Are T-Type Calcium Channel (Ca _V 3) Inhibitors. ACS Chemical Neuroscience, 2022, 13, 1395-1409.	3.5	4
294	Trans-Channel Interactions in Batrachotoxin-Modified Rat Skeletal Muscle Sodium Channels: Kinetic Analysis of Mutual Inhibition between $\hat{1}\frac{1}{4}$ -Conotoxin GIIIA Derivatives and Amine Blockers. Biophysical Journal, 2008, 95, 4266-4276.	0.5	3
295	Trans-Channel Interactions in Batrachotoxin-Modified Skeletal Muscle Sodium Channels: Voltage-Dependent Block by Cytoplasmic Amines, and the Influence of \hat{l} /4-Conotoxin GIIIA Derivatives and Permeant Ions. Biophysical Journal, 2008, 95, 4277-4288.	0.5	3
296	TMEM16C cuts pain no SLACK. Nature Neuroscience, 2013, 16, 1165-1166.	14.8	3
297	Rare functional missense variants in CACNA1H: What can we learn from Writer's cramp?. Molecular Brain, 2021, 14, 18.	2.6	3
298	Ethosuximide inhibits acute histamine- and chloroquine-induced scratching behavior in mice. Molecular Brain, 2021, 14, 46.	2.6	3
299	The calcium channel terminator: hasta la vista pain. Trends in Pharmacological Sciences, 2022, 43, 801-803.	8.7	3
300	Biochemical and biophysical studies of the interaction of class I antiarrhythmic drugs with the cardiac sodium channel. Drug Development Research, 1994, 33, 277-294.	2.9	2
301	Pain control: What a pain!. Drug Development Research, 2001, 54, 117-117.	2.9	2
302	Use â€~em and Lose â€~em—Activity-Induced Removal of Calcium Channels from the Plasma Membrane. Neuron, 2007, 55, 539-541.	8.1	2
303	Making the T-Type Even Tinier: Corticotropin-Releasing Factor-Mediated Inhibition of Low-Voltage-Activated Calcium Channel Activity: Fig. 1 Molecular Pharmacology, 2008, 73, 1589-1591.	2.3	2
304	Welcome to "Ion Channels: Key Therapeutic Targets― Future Medicinal Chemistry, 2010, 2, 689-690.	2.3	2
305	Antiallodynic effects of a confused \hat{l}_{\pm} -conotoxin: Vc1.1 relieves neuropathic pain via off target actions on GABAB receptors and N-type channels. Pain, 2011, 152, 241-242.	4.2	2
306	The truth in complexes: perspectives on ion channel signaling nexuses in the nervous system. Frontiers in Cellular Neuroscience, 2014, 8, 406.	3.7	2

#	Article	IF	CITATIONS
307	All roads lead to presynaptic calcium channel inhibition by the ghrelin receptor: Separate agonist-dependent and -independent signaling pathways. Journal of General Physiology, 2015, 146, 201-204.	1.9	2
308	The Triggle effect. Biochemical Pharmacology, 2015, 98, 322-326.	4.4	2
309	Surfen is a broad-spectrum calcium channel inhibitor with analgesic properties in mouse models of acute and chronic inflammatory pain. Pflugers Archiv European Journal of Physiology, 2017, 469, 1325-1334.	2.8	2
310	Splice-variant specific effects of a CACNA1H mutation associated with writer's cramp. Molecular Brain, 2021, 14, 145.	2.6	2
311	Voltage-Dependent Inactivation of Voltage Gated Calcium Channels. , 2005, , 194-204.		2
312	Modulation of High Voltage-Activated Calcium Channels by G Protein-Coupled Receptors. , 2004, , 331-367.		2
313	The amino terminus of high-voltage-activated calcium channels. Channels, 2014, 8, 370-375.	2.8	1
314	Protocol for detecting plastic changes in defined neuronal populations in neuropathic mice. STAR Protocols, 2021, 2, 100698.	1.2	1
315	Reciprocal Regulation of Neuronal Calcium Channels by Synaptic Proteins. , 2013, , 61-78.		1
316	Voltage-Gated Ion Channels as Molecular Targets for Pain. , 2016, , 415-436.		1
317	$\text{CaV}\hat{\text{I}}^2\text{-subunit}$ dependence of forward and reverse trafficking of CaV1.2 calcium channels. Molecular Brain, 2022, 15, 43.	2.6	1
318	Editorial. Current Topics in Medicinal Chemistry, 2005, 5, 527-527.	2.1	0
319	Prion protein attenuates excitotoxicity by inhibiting NMDA receptors. Journal of Cell Biology, 2009, 185, 1127-1127.	5.2	0
320	Welcome to â€~Clinical Pharmacology of Ion Channels'. Expert Review of Clinical Pharmacology, 2010, 3, 261-261.	3.1	0
321	Tâ€ŧypes make your clock tick. Journal of Physiology, 2015, 593, 757-758.	2.9	0
322	David Yue (1957–2014). Journal of Physiology, 2015, 593, 1325-1325.	2.9	0
323	Regulation of pain signaling by the innate immune system. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2020, 93, 2-S24-1.	0.0	0
324	SUMO wrestling in the cellular dohyÅ: crosstalk between phosphorylation and SUMOylation of PKCÎ′ regulates oxidative cell damage. FEBS Journal, 2021, 288, 6406-6409.	4.7	0

#	Article	IF	CITATIONS
325	Prion protein attenuates excitotoxicity by inhibiting NMDA receptors. Journal of Experimental Medicine, 2008, 205, i13-i13.	8.5	0
326	Prion Protein's Protection Against Pain. , 2013, , .		0
327	Voltage-gated calcium channels as molecular targets for pain therapeutics. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY19-2.	0.0	0
328	Determinants of G Protein Inhibition of Presynaptic Calcium Channels., 2005, , 154-167.		0